Regal Investment Fund (ASX:RF1) investment manager, Regal Funds Management, confirmed that it holds a 5.6% stake in Opthea (ASX: OPT) prior to the biopharmaceutical company's results of its study, according to a Tuesday filing with the Australian bourse.
Opthea said Monday that its Combination OPT-302 with Aflibercept (COAST) study in patients with age-related Macular Degeneration, failed to meet its primary endpoint and added there is significant doubt about its ability to continue as a going concern.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。